2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Genomics, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Young Adult
PAPER

3880 Evolution of Richter transformation in Canada: A national real-world study from the Canadian CLL research group (CanCLL)

Alina S. Gerrie, MD, FRCPC, MPH, Jean-Nicolas Champagne, MD2, Steven JT Huang, MSc3, Versha Banerji, MD4, Isabelle Fleury, MD MSc5, Aixiang Jiang, PhD6, Jean-Francois Larouche, MD7, Shannon Murphy, MD, MBA8, Carolyn Owen, MD9, Anthea Peters, MD, MSc, FRCPC10, Robert Puckrin, MD11, Catherine Sohier-Poirier, MD12, Cynthia Toze, MD, MSc, FRCPC13, Abi Vijenthira, MD, MS14
1 BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, British Columbia, Canada
2 Hôpital Sacré-Coeur de Montréal, Montreal, Quebec, Canada
3 BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada
4 CancerCare Manitoba, University of Manitoba, Winnipeg, British Columbia, Canada
5 Centre hospitalier universitaire (CHU) de Quebec, Universite Laval, Quebec City, Quebec, Canada
6 BC Cancer Centre for Lymphoid Cancer, Vancouver, Canada
7 Centre hospitalier universitaire (CHU) de Quebec, Universite Laval, Quebec City, Quebec, Canada
8 Dalhousie University, Halifax, Nova Scotia, Canada
9 Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
10 Cross Cancer Institute and University of Alberta, Edmonton, Alberta, Canada
11 Cross Cancer Institute and University of Alberta, Calgary, Alberta, Canada
12 Centre hospitalier universitaire (CHU) de Quebec, Universite Laval, Quebec City, Canada
13 Leukemia/BMT Program of BC and University of British Columbia, Vancouver, British Columbia, Canada
14 Princess Margaret Cancer Centre and University of Toronto, Toronto, British Columbia, Canada

Background: Richter transformation (RT) is the most aggressive complication of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); however, contemporary real-world outcomes after RT remain poorly defined. The Canadian CLL Research Group (CanCLL) was established to facilitate collaborative research across Canada. We present the first national CanCLL report, evaluating the clinical characteristics, management, and outcomes of patients (pts) with RT across Canada.

Methods: Pts with CLL/SLL and RT diagnosed between 2000-2025 were identified through participating CanCLL centres. Hodgkin lymphoma transformation was excluded. Data were collected retrospectively from institutional databases and chart review using a standardized template. Pts were compared by RT diagnosis before vs after 2016, corresponding to targeted therapy introduction for CLL/SLL in Canada.

Results: 450 RT pts were identified across 5 provinces (British Columbia, Alberta, Ontario, Quebec, and Nova Scotia) including diffuse large B-cell NOS (85%; n=384), high-grade B-cell (2.9%; n=13), and plasmablastic (0.4%; n=2). 51 (11%) pts had clinical RT without histologic confirmation. Median age at RT was 71 years (y) (range 39 – 95), 66% male, with median time from CLL/SLL diagnosis 5.1y (range 0–29.5). Of the 441 pts with CLL/SLL treatment data, pts had median 1 prior CLL-directed therapy (range 0–7) with 39% (n=171) untreated. Prior therapies included chemotherapy 55%, anti-CD20 38%, BTKi 22% and BCL2i 6%; 24 pts (5%) received targeted therapy alone.

At RT, 87% had Ann Arbor stage 3-4, 50% B symptoms, 33% ECOG 2–4, 62% elevated LDH, 21% tumor bulk >10cm and 6% CNS involvement. 88/370 (24%) had IPI 4–5 and 66/219 pts (30%) had TP53 aberrations. Only 49 pts (11%) had clonality assessed, of which 37 (75%) were clonally related (53% molecular testing; 22% light-chain restriction). Of the 442 pts with RT treatment data, the majority (76%; n = 335) received CHOP-like regimens, with addition of rituximab (R) in 305 and novel agents (BTKi/BCL2i) in 5, while others received venetoclax(R) (2%; n=7), single-agent chemotherapy (3%; n=12), other systemic regimens (n=13; 3%) or local therapy (n=16; 4%); 61 pts (14%) had no therapy due to frailty. 43 pts (10%) had a consolidative transplant (31 allo; 12 auto) in 1st (n=28) or 2nd (n=15) remission and 10 had CAR T-cell therapy (1 in 1L RT, 9 in 2L+).

With median follow-up (f/u) of 6.8y (range 0-21.8), median PFS was 6.0 months (m) (95%CI 5.0–7.2) and OS 11.9m (95%CI 8.8-14.4). 2y/5y PFS were 27%/19%, while 2y/5y OS were 38%/26%. Baseline characteristics, PFS (p=.69) and OS (p = .74) did not statistically differ between clinical and biopsy-confirmed RT. Pts with previously untreated CLL/SLL had markedly superior survival after RT than those previously treated, with median OS 37m vs 7m,  2y OS 58% vs 26% (p<.001); median PFS 24m vs 3.9m, 2y PFS 43% vs 33% (p<.001). Pts treated with curative-intent (n = 355) had 63% ORR (42% CR), with median PFS 9.1m and OS 18.8m. OS (p=.99) or PFS (p=.62) were similar after prior chemotherapy vs targeted therapy alone. At last f/u, 201 pts (45%) relapsed. Outcomes in this group were poor, with median post-relapse OS of 4.4m (95% CI 3.1-6.2). Pts who received CAR T-cell therapy for 2L+ had a median post-relapse OS of 13.6m (95% CI 2.4-NR).

Compared with the pre-2016 era (n=216), pts diagnosed with RT after 2016 (n=234) had substantially different antecedent CLL treatment patterns, with less prior chemotherapy (p=.04) and greater exposure to anti-CD20, BTKi and BCL2i (all p<.001). RT occured later in their CLL/SLL disease course (median 6.1 vs 4.0y, p<.001) and had a trend toward higher-risk disease by IPI (27% vs 19%, p=.09). Despite these differences, neither PFS nor OS differed between eras (PFS p=.72; OS p=.87). On multivariable analysis (MVA), older age (HR 1.02, 95%CI 1.01–1.04; p=.008), prior CLL-directed therapy (HR 2.11, 95%CI 1.50–2.99; p<.001), and platelet count <100×10⁹/L (HR 1.54, 95% CI 1.10–2.16; p=.013) were independently associated with inferior OS.

Conclusion: In this large national real-world study, despite substantial changes in CLL/SLL treatment following the introduction of BTK and BCL2is, survival after RT remains unchanged. These findings highlight that advances in CLL/SLL therapy have not yet translated into improved RT outcomes and underscore the need to define modern RT biology and develop more effective therapies for this high-risk population.

Alina S. Gerrie, MD, FRCPC, MPH: AbbVie - Honoraria; BeOne Medicines - Honoraria; Merck - Honoraria; AstraZeneca - Honoraria; Lilly Canada - Honoraria; Lilly Canada - Research Funding; Roche - Research Funding; Janssen - Research Funding; BeOne Medicines - Research Funding; AstraZeneca - Research Funding; AbbVie - Research Funding; Nurix - Research Funding